Ind-Swift LaboratoriesNSE:INDSWFTLAB +3.65%52 EBITDA Margin % is 12.11% as of Mar. 2026, which is 46% below its 10-year median of 22.23. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 52/100 and a GF Value™ of ₹37.17 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Ind-Swift Laboratories ranks better than 53.61% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ind-Swift Laboratories EBITDA Margin % Related Terms
Ind-Swift Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ind-Swift Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ind-Swift Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ind-Swift Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a EBITDA Margin % of 12.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ind-Swift Laboratories and its competitors. This is 46% below median its historical median of 22.23. Over the past decade, Ind-Swift Laboratories' EBITDA Margin % has ranged from 12.64 to 49.67. According to the industry distribution chart, Ind-Swift Laboratories ranks #443 out of 955 companies in the Drug Manufacturers industry, placing it in the top 46.4%.
Is Ind-Swift Laboratories' EBITDA Margin % too high?
Ind-Swift Laboratories' current EBITDA Margin % of 12.11% is 46% below median its 10-year median of 22.23. Over the past 10 years, this metric has ranged from a low of 12.64 to a high of 49.67. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Ind-Swift Laboratories' value of 12.11% is 2.7% below this industry median. Based on the distribution chart, Ind-Swift Laboratories ranks #443 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ind-Swift Laboratories has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ind-Swift Laboratories ranks #443 out of 955 companies for EBITDA Margin %. This puts Ind-Swift Laboratories in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Ind-Swift Laboratories' value of 12.11% is 2.7% below this benchmark. Historically, Ind-Swift Laboratories' own EBITDA Margin % has ranged from 12.64 to 49.67 over the past decade. While the company's 10-year median is 22.23 vs. the industry median of 12.44, Ind-Swift Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ind-Swift Laboratories's current EBITDA Margin % of 12.11% is 2.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ind-Swift Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ind-Swift Laboratories's current EBITDA Margin % is 12.11%, which is 46% below median its own 10-year median of 22.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹37.17, compared to a current price of ₹200.90 — trading 440.5% above its estimated fair value. The current EBITDA Margin % is 12.11%, which is 46% below median its 10-year median of 22.23 and 2.7% below the Drug Manufacturers industry median of 12.44. Ind-Swift Laboratories' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current EBITDA Margin % is 12.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹200.90 is trading 440.5% above its estimated GF Value™ of ₹37.17.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:INDSWFTLAB:
EBITDA Margin %: 12.11% (46% below median its 10-year median of 22.23)
GF Value™: ₹37.17 vs. price of ₹200.90 (440.5% above fair value)
Industry Position: 2.7% below the Drug Manufacturers median (#443 of 955)
No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
52GF Score
Get the complete analysis for NSE:INDSWFTLAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDSWFTLAB has been successfully added to your 
